Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease.
Sara Salvador-MartínGemma Pujol-MuncunillFerran BossacomaVíctor Manuel Navas-LópezCarmen Gallego-FernándezOscar SegarraSusana ClementeRosana Muñoz-CodoceoJavier ViadaLorena MagallaresEva Martínez-OjinagaAna Moreno-ÁlvarezAlfonso Solar-BogaInés LoverdosVicente Merino-BohórquezMaría Jesús Balboa-VegaAlejandro Rodriguez-MartinezConcepción Álvarez Del Vayo-BenitoCesar SanchezMar TolinJosé Antonio Blanca-GarcíaRuth García-RomeroFrancisco Javier EizaguirreJosé Germán Sánchez-HernandezRafael Gonzalez de CaldasAntonio Millán-JimenezElena AznalJudith Abarca-ZabalíaMaría Sanjurjo-SáezLuis Andrés López-FernándezPublished in: British journal of clinical pharmacology (2020)
Genotyping of these DNA variants before starting treatment may help to select the best anti-TNF drug in paediatric patients. The SNP rs1816702 is the most promising marker for tailoring the anti-TNF regimen in children with IBD. For the first time, DNA variants are associated with trough serum anti-TNF levels.